BioCryst Pharmaceuticals BCRX Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's total cost of revenue?
- BioCryst Pharmaceuticals (BCRX) reported total cost of revenue of $5.38M in Q1 2026.
- How has BioCryst Pharmaceuticals's total cost of revenue changed year-over-year?
- BioCryst Pharmaceuticals's total cost of revenue increased by 17.7% year-over-year, from $4.57M to $5.38M.
- What is the long-term trend for BioCryst Pharmaceuticals's total cost of revenue?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's total cost of revenue has grown at a 27.5% compound annual growth rate (CAGR), from $7.23M to $19.08M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.